Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Maxcyte's Other Non-Current Assets rose 14557.56% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 14557.56%. This contributed to the annual value of $1.5 million for FY2024, which is 29484.54% up from last year.
  • According to the latest figures from Q3 2025, Maxcyte's Other Non-Current Assets is $2.6 million, which was up 14557.56% from $2.8 million recorded in Q2 2025.
  • Maxcyte's 5-year Other Non-Current Assets high stood at $2.8 million for Q2 2025, and its period low was $295000.0 during Q1 2024.
  • Over the past 5 years, Maxcyte's median Other Non-Current Assets value was $864750.0 (recorded in 2022), while the average stood at $1.1 million.
  • In the last 5 years, Maxcyte's Other Non-Current Assets soared by 83421.83% in 2021 and then plummeted by 6214.81% in 2023.
  • Quarter analysis of 5 years shows Maxcyte's Other Non-Current Assets stood at $316700.0 in 2021, then soared by 155.45% to $809000.0 in 2022, then crashed by 52.04% to $388000.0 in 2023, then soared by 294.85% to $1.5 million in 2024, then soared by 68.47% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.8 million for Q2 2025, and $1.9 million during Q1 2025.